CD19 and Miyoshi myopathy: Targeting the kappa light chain with CAR T cells in MM reduces toxicities, such as B-cell aplasia, hypogammaglobulinemia, and impaired humoral immunity, as seen with CD19 CAR T cell therapy, which is able to target the whole B cell lineage [29].